DBL Dacarbazine

DBL Dacarbazine

dacarbazine

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

DKSH
Concise Prescribing Info
Contents
Dacarbazine
Indications/Uses
Metastatic malignant melanoma & various sarcomas.
Dosage/Direction for Use
4.5 mg/kg daily for 10 days, may be repeated every 4 wk or 250 mg/m2  daily for 5 days, may be repeated every 3 wk.
Contraindications
Hypersensitivity. History of severe myelosuppression. Pregnancy & lactation.
Special Precautions
Haematopoietic depression. Hepatic toxicity accompanied by hepatic vein thrombosis & hepatocellular necrosis (Budd-Chiari syndrome). Monitor RBC, WBC & platelets carefully. Extravasation. Avoid food intake for 4-6 hr prior to treatment. Avoid contact w/ skin & eyes. Live virus & oral poliovirus vaccine immunisation. Increased incidence of microbial infection, delayed healing & gingival bleeding. Concomitant use w/ other antineoplastic drug. Renal & hepatic impairment.
Adverse Reactions
Nausea, vomiting, diarrhoea; bone marrow depression, leucocytopenia, thrombocytopenia; Budd-Chiari syndrome.
Drug Interactions
Hastened activation to AIC w/ barbiturates, rifampicin, phenytoin. Potentiated activity of mercaptopurine, azathioprine, allopurinol. Altered incidence or severity of side effects w/ other antineoplastic agents. Increased leucopenic &/or thrombocytopenic effects w/ other medications causing these effects. Additive bone marrow depression w/ other bone marrow depressants or radiation therapy. Acute lung toxicity w/ fotemustine. Potentiated live virus vaccine replication, increased adverse effects of vaccine, decreased Ab response to vaccine.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01AX04 - dacarbazine ; Belongs to the class of other alkylating agents. Used in the treatment of cancer.
Presentation/Packing
Form
DBL Dacarbazine inj 200 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in